Kelun-Biotech's HER2 ADC Trastuzumab Botidotin Outperforms T-DM1 in Phase III Trial
Event summary
- Kelun-Biotech's trastuzumab botidotin demonstrated superior efficacy over T-DM1 in a Phase III trial for HER2-positive unresectable or metastatic breast cancer, with a median PFS of 11.1 months vs. 4.4 months (HR=0.39).
- The study, published in the Journal of Clinical Oncology (IF=44.7), showed trastuzumab botidotin achieved a 76.9% ORR and a median DoR of 12.2 months, compared to 53.0% ORR and 5.7 months DoR for T-DM1.
- Trastuzumab botidotin exhibited a favorable safety profile with lower incidences of hematologic, hepatic, and gastrointestinal toxicities, and fewer serious adverse events than T-DM1.
- The drug has been approved by China's NMPA for second-line or later treatment of HER2-positive breast cancer, marking the first domestically developed HER2 ADC approved for this indication in China.
The big picture
Kelun-Biotech's trastuzumab botidotin represents a significant advancement in HER2-targeted therapies, offering a domestically developed alternative to T-DM1 with proven efficacy and safety benefits. This approval underscores China's growing capability in innovative drug development, particularly in oncology, and sets the stage for potential global competition in the HER2 ADC market. The success of this Phase III trial could accelerate the adoption of trastuzumab botidotin as a standard treatment option for HER2-positive breast cancer, both in China and internationally.
What we're watching
- Market Expansion
- Whether Kelun-Biotech can leverage this approval to expand trastuzumab botidotin's market reach beyond China, potentially competing with established HER2-targeted therapies globally.
- Clinical Pipeline
- The pace at which Kelun-Biotech advances its ongoing Phase 2 study of trastuzumab botidotin in HER2-positive breast cancer patients previously treated with a topoisomerase inhibitor payload ADC.
- Competitive Dynamics
- How this Phase III success positions Kelun-Biotech against other biotech firms developing HER2-targeted ADCs, particularly in the second-line treatment space.